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Patients undergoing a panic attack (PA) or a hyperventilation attack (HVA) are sometimes admitted to 
emergency departments (EDs).  Reduced serotonin level is known as one of the causes of PA and HVA.  
Serotonin is synthesized from tryptophan.  For the synthesis of serotonin,  vitamin B6 (Vit B6) and iron 
play important roles as cofactors.  To clarify the pathophysiology of PA and HVA,  we investigated 
the serum levels of vitamins B2,  B6,  and B12 and iron in patients with PA or HVA attending an ED.  
We measured each parameter in 21 PA or HVA patients and compared the values with those from 20 
volunteers.  We found that both Vit B6 and iron levels were signiﬁcantly lower in the PA/HVA group 
than in the volunteer group.  There was no signiﬁcant diﬀerence in the serum levels of vitamins B2 or 
B12.  These results suggest that low serum concentrations of Vit B6 and iron are involved in PA and 
HVA.  Further studies are needed to clarify the mechanisms involved in such diﬀerences.
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anic attack (PA) and hyperventilation attack 
(HVA) are paroxysmal psychiatric events,  and 
the symptoms occur suddenly.  Individuals who are 
undergoing a PA or HVA are sometimes taken by 
ambulance to the emergency department (ED) of a 
hospital because of the physical and mental symptoms 
(including a feeling of fear),  and these individuals 
often experience repeated attacks [1,  2].  Radical 
treatment is sometimes needed for individuals who 
experience repeated PAs and/or HVAs.  It is neces-
sary to clarify the pathophysiology of PA and HVA 
and to establish valid means of treatment.
　 Miller et al. [3] demonstrated that a reduction of 
the brain serotonin level in patients experiencing a PA 
accelerated the attack,  while Olson et al. [4] reported,  
in preclinical studies using rats,  that the reduction of 
brain serotonin level induced hyperventilation.  Thus,  
several studies have suggested the involvement of a 
serotonin deﬁciency in the etiology of PA and HVA 
[3-6].  Serotonin is synthesized from tryptophan,  and 
it is well known that vitamin B6 (Vit B6) and iron each 
play an important role as cofactors in the synthesis of 
serotonin [7,  8].  Low serum concentrations of Vit 
B6 or iron have been reported as factors related to a 
reduction in the brain level of serotonin [9-11].  
However,  no study analyzing the relationship of PA 
and HVA onset to serum concentrations of Vit B6 and 
iron has been reported,  to the best of our knowledge.
　 The present prospective observational study com-
pared the serum levels of Vit B and iron in patients 
visiting the ED because of a paroxysmal psychiatric 
disorder (PA or HVA) with those in healthy volun-
teers.  The purpose of the study was to investigate 
whether Vit B6 and iron are related to the develop-
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ment of PA or HVA.
Materials and Methods
　 We analyzed serum levels of vitamin B2 (Vit B2),  
Vit B6,  vitamin B12 (Vit B12),  hemoglobin (Hb) and 
iron in premenopausal women diagnosed as having a 
PA or HVA who visited the ED of Atago Hospital 
(Kochi Prefecture,  Japan),  and in healthy volunteers.  
The study was approved in advance by the Ethics 
Committee of Atago Hospital,  and informed consent 
was obtained from each participant prior to the start 
of the study.  Atago Hospital is a 562-bed general 
hospital that accepts approx.  7,800 patients requiring 
critical care each year.
　 Participants. The attack group (AT) was 
composed of premenopausal women diagnosed as having 
a PA or HVA among all patients who visited the hos-
pitalʼs ED during the 1-year period from November 
2010 to October 2011.  The diagnosis of PA was based 
on the Diagnostic and Statistical Manual of Mental 
Disorders IV text revision (DSM-IVTR).  HVA was 
diagnosed based on tachypnea (other than PA);  
tachypnea is characterized by excessive ventilation 
beyond the demands from physical metabolism,  and is 
induced by psychogenic causes (stress,  fear,  anxiety 
or tension) in individuals free of physical abnormali-
ties [12].  For patients who were minors,  an explana-
tion about the study was given to the patientʼs guard-
ian,  and the guardianʼs consent was obtained before 
blood sampling and tests.  Patients who did not issue 
consent to the study,  patients with hepatic disease 
(alanine transaminase＞44U/l),  patients with kidney 
disease (serum creatinine＞0.01mg/ml),  patients with 
endocrine or inﬂammatory disease,  and patients rou-
tinely taking food supplements were excluded from this 
study.
　 The control group (Co) was composed of employees 
of the hospital or their family members who satisﬁed 
the following requirements: premenopausal women who 
gave consent to blood sampling for research purposes 
during a periodic health checkup in November 2010 
and who were free of psychiatric symptoms,  auto-
nomic nervous symptoms and headache.  Like the AT 
group,  individuals with hepatic disease,  kidney dis-
ease,  endocrine disease or inﬂammatory disease,  and 
individuals routinely taking food supplements were 
excluded from the Co group.
　 Measurements. General emergency tests and 
the measurement of serum Vit B2,  Vit B6,  Vit B12 
and iron were carried out during visits to the ED of 
Atago Hospital (AT group) or during the periodic 
health checkup (Co group).  The Co group subjects 
fasted after having dinner the previous night,  and 
blood was collected the next morning at 9 : 00 a.m.  
The methods employed for measurement were the 
lumiﬂavin ﬂuorescence method for Vit B2,  high-per-
formance liquid chromatography (HPLC) for Vit B6,  
a chemiluminescent immunoassay for Vit B12 [13] 
(BML Inc.,  Tokyo),  and colorimetry for serum iron 
[14].
　 The serum Vit B6 measurement included measure-
ments of pyridoxamine (PAM),  pyridoxal (PAL),  and 
pyridoxine (PIN).  The levels of 3 phosphonate forms 
of vitamers detected in the serum,  namely,  pyridox-
amine 5ʼ-phosphate,  pyridoxal 5ʼ-phosphate (PLP),  
and pyridoxine 5ʼ-phosphate were measured after 
conversion into PAM,  PAL,  and PIN,  respectively.  
PAM and PIN levels were less than the quantitation 
limit in all participants.  Therefore,  the Vit B6 data 
used in this study pertained completely to PAL levels.
　 Statistical analysis. Statistical data are 
expressed as median and quartiles.  A Mann-Whitney 
U test was employed for comparisons between the AT 
group and the Co group.  The magnitude of association 
between each factor and attack onset was evaluated 
using the area under a receiver operator characteris-
tic (ROC) curve.  To analyze the association of each 
factor with the independent outbreak of an attack,  a 
multivariate logistic regression analysis was carried 
out,  with factors with a p-value of 0.1 or lower serv-
ing as independent variables and the outbreak of 
attack as a dependent variable.  Mutual associations 
among factors were evaluated by variance inﬂation 
factors (VIFs).
　 It was assumed that the standard deviation of Vit 
B6 was 11ng/ml and that a diﬀerence of 10ng/ml was 
a clinically signiﬁcant diﬀerence.  Therefore,  it was 
necessary to collect data from 20 subjects in each 
group to achieve an alpha of 0.5 and a power of 0.8.  A 
p-value less than 0.05 was regarded as signiﬁcant.  The 
statistical analyses were carried out with the computer 
program SPSS 20.0 (IBM,  Chicago,  IL,  USA).
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Results
　 During the study period,  7,734 patients visited the 
Atago Hospital ED.  Of these patients,  44 premeno-
pausal women were diagnosed as having a PA or a 
HVA.  Of these patients,  21 gave informed consent 
and participated in the study (the AT group).  Twenty 
volunteers gave written consent after being fully 
informed of the study design and were enrolled in the 
study (the Co group).
　 Background variables. Table 1 shows each 
factor in the AT group and Co group.  In the AT group 
(n＝21),  10 patients were diagnosed with PA and 11 
were diagnosed with HVA.  The age did not diﬀer 
signiﬁcantly between the 2 groups (AT vs. Co) (p＝
0.1).  In the AT group,  one patient was taking oral 
contraception,  one patient was using oral benzodiaz-
epine (BZO),  one was using a selective serotonin 
reuptake inhibitor (SSRI) and oral BZO,  and one was 
taking a serotonin-norepinephrine reuptake inhibitor 
(SNRI) with a multi-acting receptor targeted antipsy-
chotic (MARTA),  sodium valproate and oral BZO.
　 Hb, Iron, Vit B2, Vit B6, and Vit B12 vari-
ables. Hb did not diﬀer signiﬁcantly (p＝0.45,  
Table 1) between the AT group (132mg/ml) and the 
Co group (132mg/ml).  The iron level was signiﬁcantly 
lower (p＜0.001) in the AT group (0.46µg/ml) than in 
the Co group (0.98µg/ml) (reference value [RV]:  
0.56-1.39µg/ml).  The Vit B6 level was also signiﬁ-
cantly lower (p＝0.002) in the AT group (6.3ng/ml) 
than in the Co group (12.8ng/ml) (RV: 4.0-19.0ng/ml).  
However,  there was no signiﬁcant diﬀerence between 
the 2 groups in terms of the Vit B2 level (AT group,  
0.023µg/ml; Co group,  0.025µg/ml; RV: 0.017-
0.046µg/ml,  p＝0.95) or the Vit B12 level (AT 
group,  428pg/ml; Co group,  468pg/ml; RV: 233-
914pg/ml,  p＝0.64) (Fig.  1).
　 Table 2 shows the area under the ROC curve 
indicating the involvement of each factor in the onset 
of PA and HVA.  The areas under the ROC curve for 
serum iron and Vit B6 were 0.82 and 0.86,  respec-
tively,  indicating the close association of these 2 fac-
tors with PA and HVA.
　 Multivariate analysis. Three factors (age,  iron 
and Vit B6) had a p-value below 0.1.  These 3 factors 
were thus adopted as independent variables for a 
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Table 2　 Area under receiver operator characteristic curve for 
each factor (Hb,  iron,  Vit B)
95% conﬁdential interval (CI)
Area under ROC curve Lower Upper
Age 0.64 0.46 0.82
Hb 0.60 0.42 0.77
Iron 0.82 0.69 0.96
Vit B6 0.86 0.74 0.97
Vit B2 0.55 0.37 0.73
Vit B12 0.61 0.43 0.80
ROC: receiver operator characteristic.
Table 1　 Age,  hemoglobin,  iron and vitamin B levels in the AT group and Co group
AT group
n＝21
Co group
n＝20 p-value
Age 26 (21,  37) 34 (29,  41) 0.1
Hb (mg/ml) 132 (124,  138) 132 (128, 140) 0.45
Iron (μg/ml) 0.46 (0.29,  0.72) 0.98 (0.78,  1.13) ＜0.001
Vit B6 (ng/ml) 6.3 (4.5,  8.7) 12.8 (8.9,  25.8) 0.002
Vit B2 (μg/ml) 0.023 (0.022,  0.028) 0.025 (0.022,  0.028) 0.95
Vit B12 (pg/ml) 428 (315,  635) 468 (382,  623) 0.64
Data shown include the median (25 th percentile,  75 th percentile) and p-value.  The iron and Vit B6 levels were signiﬁcantly lower in the 
AT group than in the Co group.  Other parameters were not signiﬁcantly diﬀerent between the 2 groups.
Table 3　 Multivariate analysis of association of age,  iron,  and 
Vit B6 with attacks
Odds Ratio (95% CI) p-value VIF
Age 0.99 (0.92-1.08) 0.89 1.11
Iron 0.96 (0.94-0.99) 0.006 1.14
Vit B6 0.90 (0.82-0.99) 0.037 1.05
VIF: Variance inﬂation factor.  A multivariate analysis was carried 
out using 3 factors (age,  iron and Vit B6) as independent factors.  
Iron and Vit B6 were identiﬁed as independent factors associated 
with the onset of PA or HVA.
multivariate analysis (Table 3).  Iron (adjusted odds 
ratio＝0.96,  p＝0.006) and Vit B6 (adjusted odds 
ratio＝0.90,  p＝0.037) were independently associ-
ated with the onset of PAs or HVAs.  The VIF of 
each factor was less than 5,  and there was no multi-
linearity among the factors.  For this model,  the 
Hosmer-Lemeshow test resulted in a p-value of 0.47.
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Fig. 1　 Comparison of iron,  Vit B6,  Vit B2,  and Vit B12 levels between the AT group and Co group.  Results of Mann-Whitney U tests 
on serum iron,  Vit B6,  Vit B2 and Vit B12 between the AT group and Co group.  Iron (0.46μg/ml and 0.98μg/ml,  p＜0.001) and Vit B6 
(6.3ng/ml and 12.8ng/ml,  p＝0.002) were signiﬁcantly lower in the AT group.  There was no signiﬁcant intergroup diﬀerence in terms of 
Vit B2 (0.023μg/ml and 0.025μg/ml,  p＝0.95) or Vit B12 (428pg/ml and 468pg/ml,  p＝0.64).
Discussion
　 In the present study,  patients who attended the ED 
and were diagnosed with PA or HVA provided mea-
surements of Hb,  Vit B2,  Vit B6,  Vit B12 and iron 
levels,  and we compared these measurements with data 
from healthy volunteers.  The results revealed signiﬁ-
cantly lower serum Vit B6 and iron levels in the 
patients with PA or HVA,  suggesting an association 
of Vit B6 and iron deﬁciency with the onset of PA and 
HVA.  There was no signiﬁcant diﬀerence in the Vit 
B2 or Vit B12 levels.  Hb also did not diﬀer signiﬁ-
cantly between the AT and Co groups.  Thus,  the 
inﬂuence of the symptoms of anemia arising from iron 
deﬁciency was ruled out.
　 PA and HVA are clinically considered as psychiat-
ric disorders triggered by factors such as anxiety,  
stress,  or depression.  However,  the exact cause or 
causes of the onset of a PA or HVA have not yet been 
identiﬁed.  From a neurobiological perspective,  sero-
tonin deﬁciency and dysfunction of serotonin neu-
rotransmission have been suggested as factors com-
monly involved in the etiology of PA and HVA [3-6].  
Serotonin is synthesized from the precursor trypto-
phan.  In the serotonin synthesis system of the brain,  
Vit B6 is a coenzyme for tryptophan hydroxylase,  
which is involved in the conversion of tryptophan into 
5-hydroxytryptophan [7],  and iron serves as a cofac-
tor for aromatic L-amino acid decarboxylase involved 
in the formation of serotonin from 5-hydroxytrypto-
phan [8].  Therefore,  a reduction in Vit B6 and iron 
levels can suppress the progression of the serotonin 
synthesis.
　 Bell et al. [5] reported serotonin deﬁciency and 
dysfunction of serotonin neurotransmission as causes 
of PA,  because serotonin at the periaqueductal gray 
matter (PAG) suppresses PA.  Hoes et al. [6] also 
considered compromised serotonergic neurotransmis-
sion as a cause of HVA.  In addition,  since PA and 
HVA have common features in terms of symptoms,  
pathophysiology and compromised serotonergic nerve 
function [15,  16] in PAG associated with the host 
defense system [17,  18],  we suspect that PA and 
HVA belong to the same serotonin-related spectrum of 
psychiatric disorders.  In the present study,  PA and 
HVA were analyzed together in a single group (AT 
group).
　 For patients with depression,  a low brain serotonin 
level is known to be a contributing factor [19],  and an 
association between depression and low serum Vit B6 
levels and iron deﬁciency has also been reported [20-
23].  These reports suggest that a serotonin level 
reduction arising from Vit B6 deﬁciency [11] or iron 
deﬁciency [24] leads to symptoms such as those of 
depression [22,  23].  The present study did not 
involve measurement of serotonin levels in the blood 
or the cerebrospinal ﬂuid,  and thus we do not know 
whether a reduction in serotonin level resembling that 
seen in patients with depression existed in the PA/
HVA patients.
　 For the measurement of Vit B6,  serum PLP 
evaluation is often used.  In the present study,  how-
ever,  we adopted the method of measuring PAL after 
conversion from PLP because we usually measure 
PAL in our clinical department.  Analyses of Vit B 
levels should take into account circadian variations and 
the inﬂuence of a meal consumed shortly before mea-
surement.  The AT group was allowed to take meals 
freely,  whereas the Co group fasted for 12h or more 
before their measurements were taken.  The Vit B 
levels would therefore be expected to be lower in the 
Co group than in the AT group.  Interestingly,  how-
ever,  the Vit B6 levels were lower in the AT group 
than in the Co group.
　 Moreover,  we could not determine whether the 
reductions in Vit B6 and iron levels were secondary to 
the PA and HVA,  or were the primary cause.  The 
possible reasons for a reduction in Vit B6 and iron 
levels include a decrease in the intake of Vit B6 and 
iron due to illness,  and the inﬂuence of medication.  
However,  regarding a decrease in intake due to ill-
ness,  the AT and Co patientsʼ Vit B2 and Vit B12 
levels showed no reduction.  This suggests that an 
extreme shortage of nutrient intake is unlikely in 
patients with PA or HVA.  Regarding of medication,  
only four AT patients were taking medications.  
Therefore,  the inﬂuence of medication seemed to be 
low in the present study.
　 We could not evaluate the severity of depression in 
the patients diagnosed as having a PA or HVA,  
because the patients tended to be mentally unstable at 
the time of their visits to the ED.  It is an open ques-
tion whether the low Vit B6 and iron levels in patients 
with PA or HVA is attributable to depression or to 
the PA or HVA.
　 In addition,  although 44 women were diagnosed as 
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having PA or HVA,  only 21 of these women partici-
pated in the study (AT group).  Therefore,  patient 
selection biases also need to be taken into consider-
ation.  Another limitation of this study was the fact 
that the study was carried out at a single facility.  
Although this study was based on a power analysis,  its 
scale was small and the possibility of a Type 1 error 
is not negligible.
　 In conclusion,  patients admitted to the emergency 
department of a hospital as they were undergoing a 
panic attack or a hyperventilation attack had signiﬁ-
cantly lower serum Vit B6 and iron levels compared to 
healthy volunteers.  Further studies examining the 
eﬀects of a therapeutic intervention to elucidate how 
low serum Vit B6 and low serum iron are involved in 
the pathophysiology of panic attacks and hyperventila-
tion attacks are necessary to explore the results of the 
present study.
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